PTJ
FRTX

Paul Tudor Jones’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Paul Tudor Jones’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-33
Closed -$124K – 1445
2013
Q4 		$124K Sell
33
-80
-71% -$303K 0.01% 1187
2013
Q3 		$444K Buy
+113
New +$848K 0.02% 401

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Paul Tudor Jones's FRTX Position: Q1 2014 in Review

Paul Tudor Jones sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q1 2014, closing a stake of 33 shares — an estimated $124K sold.

Paul Tudor Jones first reported a position in FRTX in Q3 2013 and held it in 2 quarters. The position peaked at $444K in Q3 2013. 78 funds tracked by Wall St. Rank hold FRTX as of Q1 2014.

  • Paul Tudor Jones reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q1 2014 after selling out during the quarter.
  • Paul Tudor Jones sold 33 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q1 2014, an estimated $124K.
  • Paul Tudor Jones first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q3 2013 and held it in 2 quarters.
  • Paul Tudor Jones's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $444K in Q3 2013.
  • 78 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q1 2014.

Based on Tudor Investment Corp's 13F filing for Q1 2014, filed 15 May 2014.